UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE TO

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)

OF THE SECURITIES EXCHANGE ACT OF 1934

AMENDMENT NO. 5

 

 

 

AMYLIN PHARMACEUTICALS, INC.

(Name of Subject Company (Issuer))

 

B&R ACQUISITION COMPANY

(Offeror)

BRISTOL-MYERS SQUIBB COMPANY

(Offeror)

 

 

 

COMMON STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

 

032346108

(CUSIP Number of Class of Securities)

 

Sandra Leung, Esq.

General Counsel & Corporate Secretary

P. Joseph Campisi, Jr., Esq.

Vice President & Associate General Counsel

Bristol-Myers Squibb Company

345 Park Avenue

New York, New York 10154

(212) 546-4000

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

 

 

Copies to:

David Fox, Esq.

Daniel Wolf, Esq.

Kirkland & Ellis LLP

601 Lexington Avenue

New York, NY 10022

(212) 446-4800

CALCULATION OF FILING FEE

 

 

Transaction Valuation(1)   Amount of Filing Fee(2)
$5,309,403,868.82   $608,457.68

 

 

(1) Calculated solely for purposes of determining the filing fee. The calculation assumes the purchase of 163,768,702 shares of voting common stock, par value $0.001 per share. The transaction value also includes the aggregate offer price for (i) 1,552,376 shares issuable pursuant to the vesting of restricted stock units and (ii) 5,950,014 shares issuable pursuant to outstanding options with an exercise price less than $31.00 per share, which is calculated by (x) multiplying the number of shares underlying an outstanding option with an exercise price less than $31.00 by an amount equal to $31.00 minus the exercise price for such option and (y) dividing such product by $31.00.
(2) The amount of the filing fee was calculated in accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory #3 for fiscal year 2012, issued September 29, 2011, by multiplying the transaction value by 0.0001146.

 

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

Amount Previously Paid:   $608,457.68    Filing Party:    Bristol-Myers Squibb Company and B&R Acquisition Company
Form of Registration No.:   Schedule TO    Date Filed:    July 10, 2012

 

¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

 

  x Third-party tender offer subject to Rule 14d-1.
  ¨ Issuer tender offer subject to Rule 13e-4.
  ¨ Going-private transaction subject to Rule 13e-3.
  ¨ Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer.   ¨

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

 

  ¨ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
  ¨ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

 

 

 

This Amendment No. 5 to the Tender Offer Statement on Schedule TO (as may be amended from time to time, the “Schedule TO”) amends and supplements the Schedule TO relating to the tender offer by (i) B&R Acquisition Company, a Delaware corporation (“Purchaser”) and a wholly-owned subsidiary of Bristol-Myers Squibb Company, a Delaware corporation (“Parent”) and (ii) Parent, for all of the outstanding common stock, par value $0.001 per share (the “Shares”), of Amylin Pharmaceuticals, Inc., a Delaware corporation (the “Company”), at a price of $31.00 per share net to the seller in cash without interest and less applicable withholding taxes, if any, upon the terms and conditions set forth in the offer to purchase dated July 10, 2012 (the “Offer to Purchase”), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the “Letter of Transmittal”), a copy of which is attached as Exhibit (a)(1)(B), which, together with any amendments or supplements, collectively constitute the “Offer.”

All information set forth in the Offer to Purchase is incorporated by reference herein in response to Items 1 through 9 and to Item 11 in this Schedule TO and is supplemented by the information specifically provided in this Schedule TO.

Item 7

(a) Source and Amount of Funds or Other Consideration . Item 7(a) of the Schedule TO is hereby amended and supplemented by amending Section 9 (“Source and Amount of Funds”) of the Offer to Purchase by adding the following paragraphs immediately after the last paragraph of the subsection titled “Senior Notes Offering”:

“On July 31, 2012, Parent completed its previously announced Notes Offering. The Notes were issued pursuant to that certain Indenture, dated as of June 1, 1993 (the “Indenture”), between the Company and The Bank of New York Mellon, as trustee (the “Trustee”), as supplemented and amended by the Sixth Supplemental Indenture, dated as of July 31, 2012, between the Company and the Trustee (the “Supplemental Indenture”). The full text of the Indenture, which was filed as Exhibit 4(a) to Parent’s Registration Statement on Form S-3, filed on April 28, 2008, and the Supplemental Indenture, which was filed as Exhibit 99.1 of Parent’s Current Report on Form 8-K filed with the SEC on July 31, 2012, are each incorporated herein by reference.”

Item 11

(a) Agreements, Regulatory Requirements and Legal Proceedings . Item 11(a) of the Schedule TO is hereby amended and supplemented by adding the following paragraph at the end thereof:

“At 11:59 PM New York City time, on Tuesday July 31, 2012, the waiting period applicable to the Offer and the merger under the HSR Act expired. Accordingly, the condition of the Offer relating to the expiration or termination of the HSR Act waiting period has been satisfied. On August 1, Parent issued a press release announcing the expiration of the HSR Act waiting period, a copy of which is filed as Exhibit (a)(5)(O) hereto.”

Item 12

Item 12 of the Schedule TO is amended and supplemented by adding the following exhibits:

 

Exhibit

No.

     
(a)(5)(O)   Press Release issued by Bristol-Myers Squibb Company, dated August 1, 2012.
(b)(1)   Indenture dated as of June 1, 1993 between Bristol-Myers Squibb Company and The Bank of New York Mellon as trustee (incorporated by reference to Exhibit 4(a) of the Registration Statement on Form S-3, filed by Bristol-Myers Squibb on April 28, 2008).
(b)(2)   Sixth Supplemental Indenture dated as of July 31, 2012 between Bristol-Myers Squibb Company and The Bank of New York Mellon as trustee (incorporated by reference to Exhibit 99.1 of the Current Report on Form 8-K filed by Bristol-Myers Squibb on July 31, 2012).

 

2

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

B&R ACQUISITION COMPANY
By  

/s/ Demetrios Kydonieus

Name:   Demetrios Kydonieus
Title:   Vice President
Date: August 1, 2012
BRISTOL-MYERS SQUIBB COMPANY
By  

/s/ Demetrios Kydonieus

Name:   Demetrios Kydonieus
Title:   Vice President, Strategy, Alliances & Transactions
Date: August 1, 2012

 

3

EXHIBIT INDEX

 

Exhibit

No.

   
(a)(1)(A)   Offer to Purchase, dated July 10, 2012.*
(a)(1)(B)   Letter of Transmittal (including Substitute Form W-9).*
(a)(1)(C)   Notice of Guaranteed Delivery.*
(a)(1)(D)   Letter from the Information Agent to Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*
(a)(1)(E)   Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Nominees.*
(a)(1)(F)   Instruction Form to be Used with the Letter of Transmittal.*
(a)(1)(G)   Summary Advertisement as published in the Wall Street Journal on July 10, 2012.*
(a)(5)(A)   Joint Press Release of Amylin Pharmaceuticals, Inc. and Bristol-Myers Squibb Company, dated June 29, 2012 (incorporated by reference to Exhibit 99.1 to the Current Report on Form 8-K filed by Bristol-Myers Squibb Company with the Securities and Exchange Commission on July 2, 2012).*
(a)(5)(B)   Press Release issued by Bristol-Myers Squibb Company, dated July 10, 2012.*
(a)(5)(C)   Class Action Complaint dated July 3, 2012 (Maxine Phillips v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(D)   Class Action Complaint dated July 3, 2012 (Douglas Peterson v. Amylin Pharmaceuticals, Inc. et al.).*
(a)(5)(E)   Transcript of Town Hall Meeting with Bristol-Myers Squibb Company and Amylin Ohio LLC, dated July 12, 2012 and slide presentation used during the Town Hall Meeting (incorporated by reference to Exhibit (a)(5)(E) to Amendment No. 1 to the Schedule 14D-9 filed by Amylin Pharmaceuticals, Inc. with the Securities and Exchange Commission on July 17, 2012).*
(a)(5)(F)   Amylin Integration Frequently Asked Questions memorandum distributed to Amylin employees on July 17, 2012 (incorporated by reference to Exhibit (a)(5)(F) to Amendment No. 1 to the Schedule 14D-9 filed by Amylin Pharmaceuticals, Inc. with the Securities and Exchange Commission on July 17, 2012).*
(a)(5)(G)   Class Action Complaint dated July 9, 2012 (Susha Halberstam v. Amylin Pharmaceuticals, Inc.) (incorporated by reference to Exhibit (a)(5)(D) to the Schedule 14D-9 filed by Amylin Pharmaceuticals, Inc. with the Securities and Exchange Commission on July 10, 2011).*
(a)(5)(H)   Stipulated Order of Class Certification and Case Management dated July 10, 2012 (Maxine Phillips v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(I)   Amended Class Action Complaint dated July 12, 2012 (Maxine Phillips v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(J)   Class Action Complaint dated July 10, 2012 (James Warnock v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(K)   Class Action Complaint dated July 20, 2012 (Susha Halberstam v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(L)   Class Action Complaint dated July 20, 2012 (Peter Doucet v. Amylin Pharmaceuticals, Inc., et al.).*
(a)(5)(M)   Press Release issued by Bristol-Myers Squibb Company, dated July 26, 2012.*
(a)(5)(N)   Memorandum of Understanding entered into July 27, 2012 (incorporated by reference to Exhibit (a)(5)(L) to Amendment No. 4 to the Schedule 14D-9 filed by Amylin Pharmaceuticals, Inc. with the Securities and Exchange Commission on July 27, 2012).*
(a)(5)(O)   Press Release issued by Bristol-Myers Squibb Company, dated August 1, 2012.
(b)(1)   Indenture dated as of June 1, 1993 between Bristol-Myers Squibb Company and The Bank of New York Mellon as trustee (incorporated by reference to Exhibit 4(a) of the Registration Statement on Form S-3, filed by Bristol-Myers Squibb on April 28, 2008).
(b)(2)   Sixth Supplemental Indenture dated as of July 31, 2012 between Bristol-Myers Squibb Company and The Bank of New York Mellon as trustee (incorporated by reference to Exhibit 99.1 of the Current Report on Form 8-K filed by Bristol-Myers Squibb on July 31, 2012).

 

4

Exhibit

No.

   
(d)(1)   Agreement and Plan of Merger, dated June 29, 2012, by and among Amylin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and B&R Acquisition Company (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Bristol-Myers Squibb Company with the Securities and Exchange Commission on July 3, 2012).*
(d)(2)   Tender and Support Agreement, by and among Amylin Pharmaceuticals, Inc., Bristol-Myers Squibb Company, B&R Acquisition Company and certain stockholders of Amylin Pharmaceuticals, Inc., dated June 29, 2012.*
(g)   None.
(h)   None.

 

* Previously filed.

 

5

Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Amylin Pharmaceuticals, Inc. (MM) Charts.
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Amylin Pharmaceuticals, Inc. (MM) Charts.